Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors

Patterson, Dan M; Zweifel, Martin; Middleton, Mark R; Price, Patricia M; Folkes, Lisa K; Stratford, Michael R L; Ross, Phil; Halford, Sarah; Peters, Jane; Balkissoon, Jai; Chaplin, Dai J; Padhani, Anwar R; Rustin, Gordon J S (2012). Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clinical cancer research, 18(5), pp. 1415-25. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-11-2414

Full text not available from this repository. (Request a copy)

Preclinical studies show that OXi4503 (combretastatin A1 diphosphate, CA1P) is more potent than other clinically evaluated vascular-disrupting agents.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Zweifel, Martin

ISSN:

1078-0432

Publisher:

American Association for Cancer Research

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:20

Last Modified:

11 Jul 2018 17:13

Publisher DOI:

10.1158/1078-0432.CCR-11-2414

PubMed ID:

22235096

Web of Science ID:

000301040700025

URI:

https://boris.unibe.ch/id/eprint/6473 (FactScience: 211440)

Actions (login required)

Edit item Edit item
Provide Feedback